ASA/Plavix Resistance CLI
| Status: | Unknown status |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 10/14/2017 |
| Start Date: | June 2013 |
| End Date: | June 2017 |
| Contact: | Christine Tam, RN |
| Email: | christine.tam@med.usc.edu |
| Phone: | 3234426863 |
Prevalence of High On-Treatment (Aspirin and Clopidogrel) Platelet Reactivity in Patients With Critical Limb Ischemia
Critical Limb Ischemia (CLI) is defined as limb pain that occurs at rest, or impending limb
loss that is caused by severe compromise of blood flow to the affected extremity. CLI is a
major cause of death and disability (secondary to myocardial infarction, stroke and
amputation). The mortality in patients with CLI approaches 25% and 50% at one and five years
respectively. High on-treatment platelet reactivity (HPR) in patients treated with aspirin
and clopidogrel (previously referred to as "resistance") is associated with an increased risk
of recurrent cardiovascular events after percutaneous coronary interventions and acute
coronary syndromes. The prevalence and significance of HPR in patients with critical limb
ischemia treated with aspirin and/or clopidogrel is not known.
The investigators project aims to investigate the prevalence of HPR (to aspirin and
clopidogrel) in one hundred patients with diagnosis of critical limb ischemia encountered at
University of Southern California affiliated hospitals (Los Angeles County Hospital and Keck
Hospital of USC).
loss that is caused by severe compromise of blood flow to the affected extremity. CLI is a
major cause of death and disability (secondary to myocardial infarction, stroke and
amputation). The mortality in patients with CLI approaches 25% and 50% at one and five years
respectively. High on-treatment platelet reactivity (HPR) in patients treated with aspirin
and clopidogrel (previously referred to as "resistance") is associated with an increased risk
of recurrent cardiovascular events after percutaneous coronary interventions and acute
coronary syndromes. The prevalence and significance of HPR in patients with critical limb
ischemia treated with aspirin and/or clopidogrel is not known.
The investigators project aims to investigate the prevalence of HPR (to aspirin and
clopidogrel) in one hundred patients with diagnosis of critical limb ischemia encountered at
University of Southern California affiliated hospitals (Los Angeles County Hospital and Keck
Hospital of USC).
Inclusion Criteria:
- EXPERIMENTAL GROUP: Patients with a diagnosis of CLI and uninterrupted treatment with
aspirin and/or clopidogrel for at least one week before testing.
- CONTROL GROUP: 10 normal volunteers without any known co-morbidities
Exclusion Criteria:
- Chronic use of nonsteroidal anti-inflammatory drugs, thrombocytopenia (platelet count
<100 × 103/μl), use of an oral anticoagulant (warfarin), GPIIb/IIIa inhibitors, or
fibrinolytic drugs within 30 days before testing. Any documented history of
hypercoaguable states or history of medication non-compliance.
We found this trial at
1
site
Los Angeles, California 90033
213) 740-2311
Principal Investigator: Leonardo Clavijo, MD, PhD
Phone: 323-442-6863
University of Southern California The University of Southern California is one of the world’s leading...
Click here to add this to my saved trials
